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Accepted 5 July 2012AbstractObjective: The aim of this study was to assess the benefits of the 2009 International Federation of Gynecology and Obstetrics (FIGO) staging
system for survival of patients with Stage IIA1 and IIA2 cervical cancer (Cx Ca).
Materials and Methods: A study cohort of 51 patients with Stage IIA Cx Ca was retrospectively collected from the 2004e2009 hospital-based,
long-form Cx Ca data registry at Mackay Memorial Hospital (Taipei, Taiwan). The survivorship and overall survival were compared between
these two groups (Stages IIA1 and IIA2) using log-rank test.
Results: Thirty-six and 15 patients were classified into Stages IIA1 and IIA2, respectively. Stage IIA2 patients were younger than those with
Stage IIA1 disease (mean age, 47.4 vs. 55.1 years, p ¼ 0.008), but no significant difference was observed in confirmed pelvic lymph node status
(21.4% vs. 38.5%, p ¼ 0.280) between them. Although the 2-year and 5-year overall survival was better among Stage IIA1 patients, there was no
significant difference in survival between Stage IIA1 and IIA2 groups (2-year, 90.6% vs. 77.8%; 5-year, 86.3% vs. 51.9%, p ¼ 0.218).
Conclusion: Although there was a trend in survival difference between Stage IIA1 and IIA2 patients, the difference was not statistically sig-
nificant. The revised FIGO 2009 staging system for Cx Ca defines a group of Stage IIA patients with bulky tumor (Stage IIA2) that are generally
younger than Stage IIA1 patients. It is sensible to investigate an alternate or enhanced treatment scheme for Stage IIA2 patients. Ideally, the
treatment scheme should prevent unnecessary radical surgery if a patient can be exposed to either chemotherapy or radiotherapy, alone or in
combination.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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The International Federation of Gynecology and Obstetrics
(FIGO) staging system is used by gynecologic oncologists
worldwide for therapeutic decision making for cervical cancer* Corresponding author. Department of Obstetrics and Gynecology, Mackay
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http://dx.doi.org/10.1016/j.tjog.2013.01.006(Cx Ca). Although prognostic factors such as primary tumor
size, pelvic lymph node (LNP) metastasis, stromal invasion,
and lymphovascular space invasion have been correlated with
patient outcome in many studies [1e5], tumor size alone de-
fines the FIGO staging of patients with Cx Ca [6]. The pub-
lished experience on the clinical role of tumor size cutoff
represents a collective effort of many clinicians over the past
decade (Table 1). The tumor size cut-off value of 4 cm is an
important criterion for both Stages 1B and IIA Cx Ca. Tumor
extension >4 cm is often referred to as bulky tumor. Thecs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Literature concerning the effect of different tumor sizes on the survival of stage IIA cervical cancer patients.
Author (y) Study design FIGO stage Tumor
size (cm)
Pts (n) Treatment type 5-y OS Recurrence
rate
LNP
Landoni et al (1997) [7] RCT IB-IIA 4 115 RH 87%
>4 55 70%
4 113 RT 90%
>4 54 72%
Perez et al (1998) [14] Retrospective (Hospital-
based)
IIA 2 15 RT 93%a
2.1e4 50 63%a
4.1e5 29 39%a
>5 20 59%a
Huang et al (2003) [8] Prospective (Hospital-based) IB-IIA 4 162 RH þ Pre-NACT 69%
Horn et al (2007) [31] Retrospective (Hospital-
based)
IIA-IIB 4 113 RH 67.7% 28.0% 42.4%
>4 132 49.5% 40.2% 60.2%
Eifel et al (2009) [15] Retrospective (Hospital-
based)
IB-IIB 4 2386 (1) 12.2% RH 85%
(2) 2.6% RHþpost-RT
>4, 6 1240 (3) 77.7% RT 69%
>6 593 (4) 7.5% RTþpost-RH 52%
Garg et al (2011) [16] Retrospective (SEER national
database)
IIA1 4 271 (1) 47.2% RT 65.8%
(2) 31.7% RHþpost-RT 40.4%
(3) 21.0% RH
IIA2 >4 289 (1) 64.7% RT 59.5% 46.0%
(2) 27.3% RHþpost-RT
(3) 8.0% RH
Lai et al (2012) (Current
study)
Retrospective (Hospital-
based)
IIA1 4 36 (1) 47% RH 86.3% 2.8% 21.4%
(2) 19.4% CCRT
(3) 16.7% RHþpost-CCRT
(4) 8.3% RHþpost-RT
(5) 5.6% BPLNDþCCRT
(6) 2.8% RT
IIA2 >4 15 (1) 46.7% RHþpost-CCRT 51.9% 6.7% 38.5%
(2) 26.7% BPLNDþCCRT
(3) 6.7% CCRT
(4) 13.3% RH
(5) 6.7% RHþpre-CT
BPLND ¼ bilateral pelvic lymphadenectomy; CT ¼ chemotherapy; CCRT ¼ concurrent chemo-radiation therapy; FIGO ¼ International Federation of Gyne-
cology and Obstetrics; LNP ¼ pelvic lymph node; NACT ¼ neoadjuvant chemotherapy; OS ¼ overall survival; post ¼ postoperative; pre ¼ preoperative;
Pts ¼ patients; RCT ¼ randomized controlled study; RT ¼ radiotherapy; RH ¼ radical hysterectomy; SEER ¼ Surveillance, Epidemiology, and End Results.
a 10-year disease-free survival.
34 J.C.-Y. Lai et al. / Taiwanese Journal of Obstetrics & Gynecology 52 (2013) 33e38prospective randomized trial by Landoni et al [7] and some
other studies [8e10] have shown that the presence of bulky
tumors significantly reduces the disease-free survival (DFS)
and cumulative overall survival (OS) for patients with Stage
IB disease regardless of the therapeutic modalities. Several
multivariate analyses, nevertheless, have failed to observe
similar correlation between bulky tumor size and survival for
Stage IB patients [11e13]. The recently revised 2009 FIGO
staging system for Cx Ca [6] also brings forth similar debates
as we have seen in the past for Stage IB patients. Stage IIA
disease is now further divided into Stages IIA1 and IIA2 using
4 cm as a discriminator. Although earlier studies have also
supported the prognostic impact of substaging Stage IIA dis-
ease [14,15], the recent study by Garg et al [16] has concluded
that the new FIGO 2009 staging criteria are not an indepen-
dent predictor of survival for Stage IIA cervical cancer. The
aim of the present study was to reassess the benefits of the2009 FIGO staging system for the survival of patients with
Stage IIA Cx Ca.
Materials and methods
Individual subject data of incident cases of Cx Ca under
examination were retrospectively collected from the
2004e2009 hospital-based, long-form Cx Ca data registry at
Mackay Memorial Hospital (MMH) (Taipei, Taiwan). The
registry belonged to a subset of dataset submitted to the
Taiwan National Cancer Registry Database, which is a popu-
lation-based cancer registry founded in 2002 by the National
Department of Health from the Executive Yuan [17]. The
dataset was then linked with the medical records of the
hospital to obtain patients’ vital status at last follow-up. The
long-form Cx Ca registry was received as de-identified patient
data. The registry collects basic demographic data and
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stage, primary tumor site, and tumor dimension at the time of
diagnosis; regional lymph node status; initial course of treat-
ment; and nature of the follow-up for vital status. Topography,
morphology, and behavior coding of the primary cancer site is
based on the third edition of the International Classification of
Diseases for Oncology (ICD-O-3), published by the World
Health Organization in 2000 [18]. All incident cases of Stages
II, IIA, IIB Cx Ca patients with the ICD-O-3 primary site code
of C53.9 were initially identified from the registry system
between January 1, 2004 and December 31, 2009. A total of
2717 Cx Ca cases were identified during the study period,
among whom 127 patients were staged as FIGO Stage IIA
disease. Seventy-one patients who received an initial course of
therapy at another hospital (16 cases); lacked microscopic
confirmation of histology (1 case); lacked pathological tumor
size information (40 cases); or died of uncertain causes or
causes other than Cx Ca (14 cases) were initially excluded
from the study to avoid survival bias. Patients were catego-
rized into the following histological groups: squamous cell
carcinoma, adenocarcinoma, adenosquamous carcinoma, and
all other histological groups. The latter group was excluded
from the analysis due to histological heterogeneity, consisting
mostly of rare histology. Three cases of rare histology (pap-
illary squamous cell carcinoma; neuroendocrine cervical car-
cinoma; villous adenocarcinoma) and one histology
inappropriate for Stage IIA disease (squamous intraepithelial
neoplasia, grade III) were removed from the remaining cases.
Another patient who was diagnosed with more than one type
of primary cancer was not considered to be typical Stage IIA1,
and was therefore precluded from this study. A total of 51
cases were therefore selected for the study. We believe that the
selected patients were homogeneous with respect to prognosis
and appropriate for this study.
All Stage IIA patients (based on 1989 FIGO recom-
mendation) were reassigned to either FIGO Stage IIA1 or IIA2
groups in accordance with the current FIGO 2009 staging
system for Cx Ca. Pathological staging is more accurate than
clinical staging, especially in Stages IB2 and II (IIA and IIB)
diseases [6,19e21]; therefore we favored the use of maximal
tumor diameter resulting from the pathological assessment of
the resection specimens in our study. The maximal tumor
diameter is the largest tumor extension of either measurement,
vertical or horizontal. All patients with pathological tumor size
40 mm or >40 mm were categorized as Stages IIA1 and
IIA2, respectively. Tumor grade 1, 2, and 3 refer to well dif-
ferentiated, moderately differentiated, and poorly differ-
entiated/undifferentiated, respectively. The data concerning
initial primary treatment were derived from procedure data
codes. Data on LNP status were derived from the confirmed
number of regional lymph nodes. The OS was defined as the
date from initial diagnosis to death or last follow-up in the
intent-to-treat population. DFS was defined as the start of
treatment until clinical or radiological evidence of recurrence.
Patients were censored if they were still alive or lost to follow-
up at last contact. Follow-up time was defined as the date of
last follow-up or death from the date of initial treatment. Thestudy was approved by the Institutional Review Boards and
Ethical Committees at MMH on 2011/07/29 (Protocol #:
11MMHIS068).
Significance levels for association between continuous and
categorical variables in different groups were computed by
Student’s t test and Pearson’s c2 as appropriate. Mean (stan-
dard deviations), frequency (%), and 95% confidence interval
(CI) were presented for continuous variable, categorical vari-
able, and survival rates, respectively. Survival analysis was
evaluated using the KaplaneMeier product-limit method, and
comparisons between survival curves were performed using
a log-rank test. All statistical tests were performed with the
use of SPSS for Windows (release R18) (SPSS Inc, Chicago,
IL, USA). All reported p values corresponded to two-sided
tests, and significance was set at an a of 0.05.
Results
The retrospective study included a study cohort of 51 Cx
Ca patients who were treated at MMH between January 1,
2004 and December 31, 2009. The clinical profiles and related
statistics of selected patients are listed in Table 2. All patients
were adults with a mean age of 53.0 years (median, 53.0 years;
range, 34e74 years) at initial diagnosis. Slightly over two-
thirds (36/51, 71%) of these patients were classified into
Stage IIA1 with a mean tumor diameter of 28.8 mm (median,
30 mm; range, 1e40 mm); and the remaining patients (15/51,
29%) were classified into Stage IIA2 with a mean tumor
diameter of 54.0 mm (median, 50 mm; range, 45e75 mm).
Stage IIA2 patients were younger than those with Stage IIA1
disease (mean age, 47.4 years vs. 55.1 years, p ¼ 0.008). The
majority of our patients were associated with squamous cell
carcinoma histological pattern (90%) and tumor grade 2
(59%). Two-third of these patients was diagnosed with Cx Ca
at another medical institute (34/51), but all patients received
their initial treatment at least partially at our hospital. In
addition, all selected patients were microscopically confirmed
positive for Stage IIA disease.
LNP status was available in 41 cases, and only 11 had LNP
metastases (11/41, 27%). The mean retrieved LNP nodes
number were 20.8  17.9 (range, 0e96) and 27.1  16.4
(range, 0e57) for Stage IIA1 and IIA2 patients, respectively.
No significant difference was observed in retrieved LNP
number (20.8 vs. 27.1, p ¼ 0.240) and confirmed LNP status
(21.4% vs. 38.5%, p ¼ 0.280) between Stages IIA1 and IIA2
group.
The majority of these patients were treated initially with
radical hysterectomy (RH) (36/51, 71%) plus bilateral pelvic
lymph node dissection (BPLND), among whom only one pa-
tient also received para-aortic lymph node dissection. Nine-
teen of these patients received only RH (19/36), but other
patients also had adjuvant treatments [1 preoperative chemo-
therapy, 3 postoperative radiotherapy, and 13 postoperative
concurrent chemotherapy plus radiotherapy (CCRT)]. Non-RH
surgery was performed in six patients (6/51), referring to those
who were treated initially with BPLND followed by post-
operative adjuvant CCRT. The remaining nine patients were
Fig. 1. Overall cumulative survival of patients with cervical cancer Stage IIA1
(n ¼ 36) and IIA2 (n ¼ 15). Differences were seen in overall survival between
the two groups. The 2-year cumulative survival rates were 90.6% and 77.8%
for Stage IIA1 and IIA2 patients, respectively; whereas the 5-year survival
rates of these patients were 86.3% and 51.9%, respectively. Statistical analysis
of survival curves were produced from the two groups of patients using log-
rank test ( p ¼ 0.218).
Table 2
Clinical profiles and related statistics of Stage IIA cervical cancer patients by
stage (n ¼ 51).
Stage IIA1 Stage IIA2 p value Stage IIA
n 36 15 51
Age (y) 55.1  9.5 47.7  6.3 0.008* 53.0  9.3
Cell type
SCC 32 (88.9%) 14 (93.3%) 46 (90.2%)
AC 3 (8.3%) 0 (0%) 3 (5.9%)
ASC 1 (2.8%) 1 (6.7%) 2 (3.9%)
Tumor gradea
Grade 1 2 (5.6%) 1 (6.7%) 3 (5.9%)
Grade 2 21 (58.3%) 9 (60%) 30 (58.8%)
Grade 3 6 (16.7%) 1 (6.7%) 7 (13.7%)
Tumor size (mm) 28.8  10.2 54.0  8.5 <0.001** 36.2  15.1
Retrieved LNP mean no. 20.8  17.9 27.1  16.4 0.240 22.6  17.5
LNP status
b
LNP meta (þ) 6 5 0.280 11
LNP meta () 22 8 30
Adjuvant treatment after non-RH surgeryc
CCRT 2 4 6
Non-surgical treatment
RT 1 0 1
CCRT 7 1 8
Adjuvant treatment before RHd
CT 0 1 1
Adjuvant treatment after RH
No Tx 17 2 19
RT 3 0 3
CCRT 6 7 13
Survival statuse
NED 29 (82.9%) 8 (57.1%) 37 (75.5%)
AWD 2 (5.7%) 2 (14.3%) 4 (8.2%)
DOD 4 (11.4%) 4 (28.6%) 8 (16.3%)
Statistical significance (p < 0.01*; p < 0.001**).
AC ¼ adenocarcinoma; ASC ¼ adenosquamous carcinoma; AWD ¼ alive
with disease; BPLND ¼ bilateral pelvic lymph node dissection;
CCRT ¼ concurrent chemo-radiation therapy; CT ¼ chemotherapy;
DOD ¼ died of disease; LNP ¼ pelvic lymph node; NED ¼ no evidence of
disease; RH ¼ radical hysterectomy; RT ¼ radiotherapy; SCC ¼ squamous
cell carcinoma; Tx ¼ treatment.
a Data of 11 cases were not available for the analysis of tumor grade.
b Data of 10 cases were not available for the analysis of LNP status.
c Bilateral pelvic lymph node dissection.
d Radical hysterectomy plus lymph node dissection.
e Data of 2 cases were not available for the analysis of survival status.
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(1/9) or CCRT (8/9).
During the study period, eight patients died from Cx Ca.
The median time from diagnosis to initial treatment was 29
days (95% CI: 26.1e31.9 days) and 41 days (95% CI:
24.6e57.4 days) for Stage IIA1 and IIA2 patients, respec-
tively. Disease status after treatment was certain only in 49
cases. Within the time frame of this analysis, six patients (6/
49, 12%) were never disease-free; among whom four (4/6,
67%) died of cancer progression at last follow-up. Only two of
the 43 patients who recurred achieved complete tumor control
after initial primary treatment, and continued to live without
recurrence for 46.5 months (95% CI: 4.4e88.6 months). One
patient (Stage IIA2) recurred locally and was treated by non-
RH surgery plus postoperative adjuvant CCRT, whereas the
other (Stage IIA1) with both local and distant recurrences was
treated by RH alone.The median survival was >5 years and the exact value was
not calculable due to insufficient median follow-up time of 29
months (95% CI: 17.0e41.0 months) for the entire cohort. The
2-year and 5-year OS rates (2-year, 83.3%; 5-year, 75.8%)
were similar to that of DFS rates (2-year, 86.6%; 5-year,
77.2%). Although the 2-year and 5-year OS rates were better
among Stage IIA1 patients, there were no significant differ-
ence in survival between Stage IIA1 and IIA2 groups (2-year,
90.6% vs. 77.8%; 5-year, 86.3% vs. 51.9%, log-rank test,
p ¼ 0.218) (Fig. 1).
Survivorship analysis indicated no statistical significance in
age, substage (IIA1 or IIA2), LNP status, histological types,
treatment types, tumor grade, surgical methods [RH with or
without postoperative adjuvant therapies such as chemotherapy,
radiotherapy, or CCRT], radiotherapy alone, and CCRT alone.
Discussion
The new FIGO 2009 staging criteria represent a major
advancement that affects diagnostic and therapeutic decisions
for pathologists and gynecologic oncologists, respectively. A
total of 51 patients were retrospectively classified using the
new FIGO 2009 staging system. Our experience shows that the
revised FIGO 2009 staging system for Cx Ca defines a group
of Stage IIA patients with bulky tumor (Stage IIA2) that are
generally younger than those with nonbulky tumors (Stage
IIA1).
Most authors would agree that the age of the patient is an
important consideration when comparing clinical roles of
reported results derived from literature available online. The
respective mean patient age for Stage IIA1 and IIA2 patients at
diagnosis were 54 and 49 years as reported by Garg et al [16] in
their study of 560 cases. Landoni et al [7] described 52 and 46
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in their RH group of 170 cases; and mean of 55 and 50 years for
their radiotherapy group of 167 cases. In our study, themean age
was 55 and 48 years for Stage IIA1 and IIA2 patients, respec-
tively. This finding concurs with other reported results in that
patients with bulky tumor (Stage IIA2) are generally younger
than those with nonbulky tumors (Stage IIA1).
The purpose of the new FIGO 2009 criteria is to determine
the survival benefit for Stage IIA Cx Ca patients with bulky
tumors (or Stage IIA2 patients). In the present study, a higher
5-year survival rate was observed in Stage IIA1 patients than
in Stage IIA2 patients, which agreed with the published
findings (Table 1). A equivalence 5-year OS rate was reported
by Eifel et al [15] on 4219 patients (40 mm, 86.3% vs. 85%;
>60 mm, 51.9% vs. 52%). However, very few studies have
been reported for Stage IIA patients alone. Most early staged
Cx Ca studies have examined outcomes of both Stages IB and
IIA patients, among whom Stage IB patients were the ma-
jority. The current study included a cohort that was composed
entirely of Stage IIA patients. Although the study cohort
reported by Garg et al [16] also consisted entirely of Stage IIA
patients, they did not observe survival difference between the
two stages. Those authors reported a much lower 5-year OS
rate for the IIA1 group (86.3% vs. 65.8%), and a slightly
higher 5-year OS rate for the IIA2 group (51.9% vs. 59.5%)
than we did. The difference in sample size between the
Surveillance, Epidemiology, and End Results (SEER) national
database in their study and the hospital registry in our study
was possibly the major reason explaining the expected dis-
cordant results between the two studies. However, a higher
proportion of patients in our study were managed by radical
surgery, which might also possibly explain the observed dis-
crepancy with the findings by Garg et al [16].
Many would agree that the presence of lymph node me-
tastases is an important prognostic factor that correlates with
an unfavorable impact on the survival of both early and
advanced Stage Cx Ca patients [7,22]. Traditionally,
advanced-stage disease includes Stage IIB or higher; however,
the National Comprehensive Cancer Network (NCCN)
guidelines now categorize patients with Stage IIA1 into the
early disease group, and those with Stage IIA2 into the
advanced disease group [23]. Advanced patients are often
considered to have a higher incidence of both para-aortic
lymph node and LNP metastasis than early stage patients.
However, because the status of distant lymph node regions was
not available in this registry, it is not possible to determine
accurately the extent of disease spread for these patients.
Nevertheless, although the difference in the incidence of LNP
metastasis was not statistically significant in our study (Table
2), the incidence of LNP metastasis was more than twofold in
patients with Stage IIA2 than those with IIA1 diseases, which
corresponded well with the advanced stage classification of
Stage IIA2 disease.
The majority of these patients in our study were treated
initially with RH followed by postoperative CCRT (Table 2).
Similar to other studies, adjuvant therapy (radiotherapy or
CCRT) plays an important role in the postoperative adjuvanttreatment of RH in the presence of increased tumor size and
LNP metastases [3,12,24,25]. However, the combined modal-
ity of RH and radiotherapy may lead to increased side effects
and significant complications [26,27]. Alternatively, compa-
rable cure rates have been reported for patients with early-
stage Cx Ca treated with either RH or radiotherapy
[7,28,29]. RH is a much more favorable alternative for young
patients who desire to preserve ovarian and improved coital
function. An additional advantage is accurate staging. Histo-
logical verification of tumor extent correlates better with the
biological behavior of disease, therefore, surgical staging is
superior to clinical staging. By contrast, the higher morbidity
associated with RH has rendered radiotherapy a more suitable
treatment option for older patients, as well as those who are
physically unfit. Nevertheless, an important consideration is
the association between increased local failure rate of primary
radiotherapy and large tumor sizes [14,30]. The choice of
therapy suitable for Stage IIA patients with bulky tumors must
therefore be carefully selected based on the clinical and sur-
gical assessments of the disease, as well as in consideration of
patient and physician preferences.
The clinicians must bear in mind some of the limitations
faced by the inherent nature of a retrospective study while
interpreting the data reported herein. Our hospital had limited
patients with bulky tumors (Stage IIA2), leading to unequal
censoring rate when compared to those with nonbulky tumors.
This weakened the univariate analysis for a hospital-based
population. Moreover, there were insufficient data to assess
the status of distant lymph node regions. Furthermore, we also
lacked information on types of RH as well as types and dos-
ages of chemotherapeutic agents.
Although the staging criteria divide the IIA patients into
just two tumor groups, the current study finds that the revised
FIGO 2009 staging system for Cx Ca defines a subgroup of
Stage IIA patients with bulky tumor (Stage IIA2) who are
generally younger than the remaining patients in Taiwan. The
respective 2-year and 5-year OS rates for Stage IIA2 patients
were 77.8% and 51.9%. Age groups, surgical methods, his-
tological types, treatment types, tumor grade, and LNP
involvement do not appear to be associated with survival
outcomes of Stage IIA patients. There was a trend of a dif-
ference in survival between the Stage IIA1 and IIA2 patients,
therefore, it is sensible to investigate an alternate or enhanced
treatment scheme for Stage IIA2 patients. Further prospective
studies with large numbers of patients should be carried out to
compare treatment protocols for Stage IIA2 patients. Ideally,
the treatment scheme should prevent unnecessary RH if the
patient can be exposed to either radiotherapy or CCRT alone.
Despite the aforementioned limitations faced by this study, its
significance lies in the fact that it is believed to be the first
Asian study to date to report experiences with Stage IIA pa-
tients using the FIGO 2009 classification. Gynecologic on-
cologists in Asia perform a higher percentage of RH when
treating patients with Stage IIA diseases, therefore, we hope
that our 51-case experience with FIGO 2009 classification
may serve as a basis of comparison for future studies on the
Asian population.
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